209 related articles for article (PubMed ID: 7448831)
1. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
4. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
5. Cooperative binding of the bisubstrate analog N-(phosphonacetyl)-L-aspartate to aspartate transcarbamoylase and the heterotropic effects of ATP and CTP.
Newell JO; Markby DW; Schachman HK
J Biol Chem; 1989 Feb; 264(5):2476-81. PubMed ID: 2644262
[TBL] [Abstract][Full Text] [Related]
6. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
9. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
10. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
11. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
13. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
Kensler TW; Jayaram HN; Cooney DA
J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
[TBL] [Abstract][Full Text] [Related]
14. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
15. A 70-amino acid zinc-binding polypeptide fragment from the regulatory chain of aspartate transcarbamoylase causes marked changes in the kinetic mechanism of the catalytic trimer.
Zhou BB; Waldrop GL; Lum L; Schachman HK
Protein Sci; 1994 Jun; 3(6):967-74. PubMed ID: 8069226
[TBL] [Abstract][Full Text] [Related]
16. Half of Saccharomyces cerevisiae carbamoyl phosphate synthetase produces and channels carbamoyl phosphate to the fused aspartate transcarbamoylase domain.
Serre V; Guy H; Penverne B; Lux M; Rotgeri A; Evans D; Hervé G
J Biol Chem; 1999 Aug; 274(34):23794-801. PubMed ID: 10446140
[TBL] [Abstract][Full Text] [Related]
17. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new transition-state analogue inhibitors of aspartate transcarbamylase.
Farrington GK; Kumar A; Wedler FC
J Med Chem; 1985 Nov; 28(11):1668-73. PubMed ID: 4067992
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Cohen RE; Schachman HK
J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
